By using our website, you agree to the use of our cookies.

Fund performance and monthly report

Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.

Rhenman Healthcare Equity L/S (RHE L/S)
January 2023
The fund performance is calculated and reported once a month.
FUND CLASSNAVSINCE PREVIOUS MONTHTHIS YEARSINCE FUND STARTSTART DATE
IC1 (EUR)823.922.02%2.02%723.92%2009-06-22
IC3 (EUR)1036.432.08%2.08%936.43%2009-07-31
IC2 (SEK)682.483.60%3.60%582.48%2012-12-31
ID1 (SEK)Distributing427.533.75%3.75%327.53%2012-04-30
IC1 (USD)200.223.79%3.79%100.22%2015-01-31
IC2 (USD)275.533.84%3.84%175.53%2014-04-30
RC1 (EUR)706.381.97%1.97%606.38%2010-08-31
RC1 (SEK)798.903.75%3.75%698.90%2009-06-22
RC2 (SEK)847.603.68%3.68%747.60%2009-06-22

 

 

NAV January 2023:
rhe L/S +2.02%
NAV January 2023:
rhe L/S YTD +2.02%
There are many good reasons to invest in the healthcare sector
NAV January 2023:
rhe L/S +2.02%
NAV January 2023:
rhe L/S YTD +2.02%
We base our investments on insights from our
Scientific Advisory Board

Rhenman Healthcare Equity L/S
("RHE L/S")

RHE L/S is a global, long-biased hedge fund that invests in the healthcare sector. Since RHE L/S was launched in June 2009, it has returned + 724 %, which corresponds to an annual average of + 17 %. RHE L/S is managed by an experienced management team and supported by the Scientific Advisory Board. Read more >

Founded in 2008, Rhenman & Partners Asset Management is a Stockholm-based asset manager focusing on managing the portfolio of a niche fund that is registered in Luxembourg: Rhenman Healthcare Equity L/S (RHE L/S), launched in 2009. The fund is managed by FundRock Management Company SA., who have commissioned Rhenman & Partners Asset Management to manage the fund's portfolio. Read more >

In 2019 Rhenman Healthcare Equity L/S celebrated its 10-year anniversary. In the clip portfolio managers Henrik and Susanna talk about the fund’s strategy, focus and expectations. Susanna highlights four areas that explain this success. Henrik shares his thoughts on the future of the healthcare sector and what to expect from the fund in the coming years.

Keep yourself updated by reading our monthly letter: Rhenman Healthcare Equity L/S. Read more >

The Scientific Advisory Board

An important reason behind our fund's great success is the co-operation between the portfolio managers and the medical experts on our Scientific Advisory Board. Read more >

Rhenman Healthcare Equity L/S

Fund development - IC1 (EUR)

Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.

For several decades, the healthcare sector has accounted for a rising share of the world’s GDP. In the US, the share has risen to 19%. In the OECD countries, the average is 12%. In emerging markets, such as China and India, shares of GDP are rising quickly, which means there is great potential. Read more >